We are joined by touchONCOLOGY European Oncology & Haematology Editor-in-Chief Dr Axel S Merseburger to discuss his highlights from the JAVELIN Bladder 100 Trial (Clinicaltrials.gov identifier: NCT02603432) and the KEYNOTE-426 phase III trial in patients with clear cell renal cell carcinoma (ClinicalTrials.gov identifier: NCT02853331).
Questions
1. What are the current unmet needs in the treatment of urothelial carcinoma and how do you see the results of the Javelin Bladder 100 trial impacting the future in this clinical setting? (0:06)
2. What were the main take-home messages from the KEYNOTE-426 phase III trial in patients with clear cell renal cell carcinoma? (3:30)
Speaker disclosure: Axel S Merseburger has no financial or non-financial conflicts of interest in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
